目的: 探讨老年人血清25-羟维生素D （25-hydroxy vitamin D,25-OH-D）、骨保护素（osteoprotegerin,OPG）、甲状旁腺素（parathyroid,PTH）、Ⅰ型胶原氨基端肽（procollagen type 1 N-terminal propeptide,P1NP）、Ⅰ型胶原羧基端肽交联（β cross-linked C-telopeptide of type 1 collagen,β-CTX）等骨代谢指标与动脉粥样硬化疾病间的相关性。方法: 入选2015年1月至2016年10月上海交通大学医学院附属瑞金医院老年病科的163例患者,分为动脉粥样硬化组（110例）及对照组（53例）,动脉粥样硬化组包括外周动脉粥样硬化组60例、冠心病组25例及脑梗死组25例。测量其血压,计算体质量指数,测定肾功能、血糖、血脂、C-反应蛋白(CRP)、25-OH-D、OPG、PTH、P1NP、β-CTX,并采用彩色多普勒超声仪行颈及下肢动脉超声检查,比较动脉粥样硬化性疾病组与对照组间的骨代谢指标变化。结果: ①163例患者的平均血清25-OH-D含量为（47.11±17.29） nmol/L,维生素D缺乏者占58.1%。②与对照组相比,动脉粥样硬化性疾病组的25-OH-D含量明显降低（P<0.05）,血清OPG、PTH水平则显著升高（P<0.05）。③相关分析提示,动脉粥样硬化性疾病与25-OH-D含量呈负相关（r=-0.559, P<0.05）,与OPG水平呈正相关（r=0.459, P<0.05）;而P1NP、β-CTX含量与动脉粥样硬化间无相关性（P>0.05）。④Logistic回归分析结果提示,血清25-OH-D和OPG是动脉粥样硬化性疾病的独立相关因素。结论: 动脉粥样硬化性疾病患者的血清25-OH-D含量明显降低,早期补充维生素D或可一定程度上减缓其动脉粥样硬化性疾病进展。血清OPG水平在动脉粥样硬化性疾病患者中显著升高可能是机体的代偿性保护作用。骨转换高低与动脉粥样硬化无关 ,但需要更进一步研究以证实。
Objective: To investigate the correlation of indicators of bone metabolism including hydroxyvitamin D (25-OH-D), osteoprotegerin (OPG), parathyroid（PTH）, procollagen type 1 N-terminal propeptide（P1NP）, β cross-linked C-telopeptide of type 1 collagen（β-CTX）with atherosclerotic disease in elderly. Methods: A total of 163 elderly patients at Department of Geriatrics, Ruijin Hospital from January 2015 to October 2016（mean age 75.8 years）were recruited. Blood pressure, BMI, plasma glucose, renal function, blood lipids, CRP, 25-OH-D, OPG, PTH, P1NP, β-CTX were measured. Both carotid and lower extremity atherosclerosis were assessed by Doppler ultrasound,and patients were divided into 2 groups: atherosclerosis group and control group. Results: ①The mean serum level of 25-OH-D in all subjects was (47.11±17.29) nmol/L and the percentage of vitamin D deficiency was 58.1%. ②Compared with the control group, serum 25-OH-D in atherosclerosis group was significantly lower (P<0.05), while OPG and PTH were significantly higher (P<0.05). ③Atherosclerotic disease was negatively correlated with 25-OH-D （r=-0.559, P<0.05）and positively correlated with OPG（r=0.459, P<0.05）by correlation analysis. ④Logistic regression analysis showed that serum 25-OH-D and OPG were independent risk factors of atherosclerotic disease. Conclusions: Patients with atherosclerotic disease have lower serum 25-OH-D level. Early vitamin D supplementation may slow down the progression of atherosclerosis. The significantly higher serum OPG in patients with atherosclerotic disease may be due to the compensatory protective effect of body. This study reveales that status of bone turnover has no relationship with atherosclerosis, yet needs to be further investigated.
[1] 陈伟伟, 高润霖, 刘力生, 等. 中国心血管病报告2016[J]. 中国循环杂志,2017,32(6):521-530.
[2] Holick MF.Vitamin D deficiency[J]. N Engl med,2007, 357(3):266-281.
[3] Jono S, Ikari Y, Shioi A, et al.Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease[J]. Circulation,2002,106(11):1192-1194.
[4] Kiechl S, Schett G, Wenning G, et al.Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease[J]. Circulation,2004,109(18):2175-2180.
[5] Nybo M, Johnsen SP, Dethlefsen C, et al.Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy popu-lation[J]. Clin Chem,2008,54(12):1969-1974.
[6] Lee JH, Gadi R, Spertus JA, et al.Prevalence of vitamin D deficiency in patients with acute myocardial infarction[J]. Am J Cardiol,2011,107(11):1636-1638.
[7] Verdoia M, Schaffer A, Sartori C, et al.Vitamin D deficiency is independently associated with the extent of coronary artery disease[J]. Eur J Clin Invest,2014,44(7):634-642.
[8] Daubail B, Jacquin A, Guilland JC, et al.Serum 25-hydroxyvitamin D predicts severity and prognosis in stroke patients[J]. Eur J Neurol,2013,20(1):57-61.
[9] Li YC, Kong J, Wei M, et al.1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system[J]. J Clin Invest,2002,110(2):229-238.
[10] Werner C, Pöss J, Böhm M.Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?[J]. Drugs,2010,70(10):1215-1230.
[11] Tamez H, Kalim S, Thadhani RI.Does vitamin D modulate blood pressure?[J]. Curr Opin Nephrol Hypertens,2013,22(2):204-209.
[12] Weng S, Sprague JE, Oh J, et al.Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice[J]. PLoS One,2013,8(1):e54625.
[13] Chen S, Law CS, Grigsby CL, et al.A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation[J]. J Steroid Biochem Mol Biol,2010,122(5):326-332.
[14] Shea MK, Booth SL, Massaro JM, et al.Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study[J]. Am J Epidemiol, 2008,167(3):313-320.
[15] Timms PM, Mannan N, Hitman GA, et al.Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory da-mage in chronic disorders?[J]. QJM,2002,95(12):787-796.
[16] Grigoropoulou P, Eleftheriadou I, Zoupas C, et al.The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease[J]. Curr Med Chem,2011,18(31):4813-4819.
[17] Tousoulis D, Siasos G, Maniatis K, et al.Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease[J]. Int J Cardiol,2013,167(5):1924-1928.
[18] Knudsen ST, Foss CH, Poulsen PL, et al.Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications[J]. Eur Endocrinol,2003,149(1):39-42.
[19] Bennett BJ, Scatena M, Kirk EA, et al.Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice[J]. Arterioscler Thromb Vasc Biol,2006,26(9):2117-2124.
[20] 马燕, 庞小芬, 张之梁, 等. 老年男性原发性高血压患者体内维生素D与骨代谢指标的水平及相关性分析[J]. 诊断学理论与实践,2015,14(3):262-266.
[21] 汪思阳, 沈展, 沈婷婷, 等. 补充维生素D对骨质疏松症和骨量减少患者骨密度和骨折风险的影响[J]. 内科理论与实践,2016,11(2):80-83.
